



Date: 02.01.2026

To
The Corporate Relation Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street Mumbai – 400001

Dear Sir / Madam,

Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018

Subject: Intimation for Appointment of an Independent Director – Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in continuation of the Company's intimation dated November 29, 2025, wherein it was informed that the Board of Directors of the Company, based on the recommendation of the Nomination and Remuneration Committee, had appointed Dr. Yogananda Moolemath (DIN: 02870387) as an Independent Director with effect from January 01, 2026, the Company hereby informs that the said appointment has been approved by the shareholders through a postal ballot, the results of which were declared on January 02, 2026.

The disclosure as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and with SEBI Master Circular in respect of aforesaid appointment is enclosed as **Annexure A**.

Kindly take the same on your record and oblige.

Thanking You

For Pharmaids Pharmaceuticals Limited

Prasanna Subramanya Bhat
(Company Secretary & Compliance Officer)



Annexure A

Details with respect to appointment of Director of the Company, as required under Regulation 30 of SEBI (LODR) Regulations, 2015 and SEBI Master Circular dated November 11, 2024.

S.No.	Particulars	Details
1	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment Dr. Yogananda Moolemath (DIN: 02870387) as an Independent Director.
2	Date of appointment and Term of appointment	Date of Appointment: January 01, 2026 Term: Appointed as an Independent Director for a consecutive term of 5 (Five) years.
3	Brief Profile	<p>Dr. Yogananda Moolemath is a European Registered Toxicologist (ERT) with a PhD in Toxicology and has over 30 years of experience in Drug Discovery & Development, toxicology, regulatory science and research leadership.</p> <p>He is presently serving as Chief Scientific Officer & Co-Founder of Vittarthaa Life Sciences and has held senior positions in reputed pharmaceutical and CRO organisations.</p> <p>He was also associated with St. John's National Academy of Health Sciences, Bangalore as an Adjunct Associate Professor, and has authored multiple peer-reviewed research publications with global regulatory submissions.</p>
4	Disclosure of relationships between directors (in case of appointment of a director)	He is not related to any of the Directors on the Board of the Company
5	Information as required pursuant to BSE Circular No. L1ST/COMP/ 14/2018-19 dated 20th June, 2018	He is not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority.